May 2009  << Back  

  Can't open the PDF? Click here for help.

 

 EDITORIAL

AACP provides you with vital clinical information in print, online, and in person

Donald W. Black, MD

Editor-in-Chief

The partnership between the American Academy of Clinical Psychiatrists (AACP) and Quadrant HealthCom Inc. announced in February 2009 got off to a great start with our first jointly sponsored educational meeting, “Bipolar disorder and ADHD: Solving clinical challenges, improving patient care,” held in Chicago in April. The well-attended and lively event attracted clinicians from around the country who heard from leading experts about how to care for patients with bipolar disorder, attention deficit/hyperactivity disorder, or both. I saw many old friends and made new ones, all enthusiastic about the redesigned Annals of Clinical Psychiatry.

Annals’ online submission and peer-review system at http://mc.manuscriptcentral.com/uacp has been a success. In fact, the time from submission to final acceptance now averages 44 days. I salute my many peer reviewers for completing their reviews so quickly.

I urge Annals readers to visit the redesigned AACP Web site (www.AACP.com) and all that it has to offer:

  • AACP mission and goals

  • membership and benefit information

  • upcoming meetings

  • abstracts and full-text articles from Annals

  • medical job opportunities.

We will soon add an electronic newsletter to notify members about upcoming AACP activities. The redesign has been spearheaded by Nagy Youssef, MD.

This issue of Annals continues our traditional focus on issues important to clinicians. We begin with original research articles. Roseanne DeFronzo Dobkin, PhD, and colleagues report positive results from an open-label trial of escitalopram in the treatment of hot flashes in menopausal women. There are relatively few options to treat these often troubling symptoms, and this finding could help many women find relief. Next, Hristina K. Koleva, MD and her colleagues present 3 cases of edema thought to be associated with quetiapine. Because quetiapine is so widely prescribed, it is not surprising that new side effects continue to be reported. Dan J. Stein, MD, PhD, and colleagues compare the functional recovery and relapse in patients with anxiety symptoms based on a reanalysis of data collected in several clinical trials that included patients with generalized anxiety disorder and social phobia. Mark Hamner, MD, and colleagues report that divalproex is no better than placebo for the treatment of posttraumatic stress disorder. Although these findings are disappointing, this article highlights the importance of negative studies.

We also present 3 review articles. William R. Yates, MD, provides clinicians with the most current data on the prevalence, risk factors, and consequences of panic disorder. Next, Kanwaldeep S. Sidhu, MD, reviews the literature on the use of the standard electroencephalogram in the evaluation of delirium and confirms that diffuse slowing is one of the hallmarks of the encephalopathic process. Lastly, Dan J. Stein, MD, PhD, compares Japanese taijin kyofusho with the Western concept of social phobia.

I invite readers to contact me at donald-black@uiowa.edu. I am always seeking new material for Annals and am happy to discuss your ideas.